摘要
目的探讨高血压合并血脂代谢紊乱患者行苯扎贝特片联合氨氯地平片治疗的临床效果。方法82例高血压合并血脂代谢紊乱患者,按治疗方法不同分为实验组和对照组,各41例。实验组患者应用苯扎贝特片联合氨氯地平片治疗,对照组患者应用氨氯地平片治疗。比较两组治疗前后血压、血脂、血管内皮因子水平及不良反应发生情况。结果治疗后,实验组收缩压(120.24±8.76)mm Hg(1 mm Hg=0.133 kPa)和舒张压(77.68±10.12)mm Hg均低于对照组的(137.78±8.64)、(94.56±11.04)mm Hg,差异有统计学意义(P<0.05)。治疗后,实验组总胆固醇为(5.11±0.22)mmol/L、甘油三酯为(1.31±0.24)mmol/L、低密度脂蛋白胆固醇为(2.03±0.16)mmol/L、高密度脂蛋白胆固醇为(1.14±0.39)mmol/L,对照组总胆固醇为(5.94±0.66)mmol/L、甘油三酯为(2.71±0.59)mmol/L、低密度脂蛋白胆固醇为(2.91±0.33)mmol/L、高密度脂蛋白胆固醇为(0.74±0.28)mmol/L;治疗后,实验组总胆固醇、甘油三酯、低密度脂蛋白胆固醇均低于对照组,高密度脂蛋白胆固醇高于对照组,差异有统计学意义(P<0.05)。治疗后,实验组一氧化氮为(28.34±5.14)μmol/L、一氧化氮合酶为(26.37±4.35)μmol/L、内皮素-1为(80.16±6.74)pg/ml,对照组一氧化氮为(24.61±5.25)μmol/L、一氧化氮合酶为(22.04±4.09)μmol/L、内皮素-1为(88.14±7.16)pg/ml;治疗后,实验组一氧化氮、一氧化氮合酶均高于对照组,内皮素-1低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论苯扎贝特片联合氨氯地平片治疗高血压合并血脂代谢紊乱能够科学控制患者的血压与血脂水平,改善血管内皮细胞功能,治疗更安全,值得临床推广。
Objective To discuss the clinical effect of bezafibrate tablets combined with amlodipine tablets for hypertension patients with dyslipidemia.Methods A total of 82 cases of hypertension patients with dyslipidemia were divided into an experimental group and a control group according to different treatment methods,with 41 cases in each group.The experimental group was treated with bezafibrate tablets and amlodipine tablets,and the control group was treated with amlodipine tablets.The blood pressure,blood lipids and vascular endothelial growth factor levels before and after treatment,and adverse reactions were compared between the two groups.Results After treatment,the systolic blood pressure of(120.24±8.76)mm Hg(1 mm Hg=0.133 kPa)and diastolic blood pressure of(77.68±10.12)mm Hg in the experimental group were lower than those of(137.78±8.64)and(94.56±11.04)mm Hg in the control group.The differences were statistically significant(P<0.05).After treatment,the total cholesterol in the experimental group was(5.11±0.22)mmol/L,the triglyceride was(1.31±0.24)mmol/L,the low density lipoprotein cholesterol was(2.03±0.16)mmol/L,and the high density lipoprotein cholesterol was(1.14±0.39)mmol/L;in the control group,total cholesterol was(5.94±0.66)mmol/L,the triglyceride was(2.71±0.59)mmol/L,the low density lipoprotein cholesterol was(2.91±0.33)mmol/L,and the high density lipoprotein cholesterol was(0.74±0.28)mmol/L.After treatment,the total cholesterol,triglyceride and low density lipoprotein cholesterol in the experimental group were lower than those in the control group,and the high density lipoprotein cholesterol was higher than that in the control group.The differences were statistically significant(P<0.05).After treatment,the nitric oxide in the experimental group was(28.34±5.14)μmol/L,the nitric oxide synthase was(26.37±4.35)μmol/L,and the endothelin-1 was(80.16±6.74)pg/ml;in the control group,the nitric oxide was(24.61±5.25)μmol/L,the nitric oxide synthase was(22.04±4.09)μmol/L and the endothelin-1 wa
作者
曹兴阳
CAO Xing-yang(Yingkou Central Hospital,Yingkou 115000,China)
出处
《中国现代药物应用》
2023年第23期130-133,共4页
Chinese Journal of Modern Drug Application
